Ranbir Kapoor’s entrepreneurial venture, ARKS, officially launches today with a debut collection of elevated essentials that ...

Indian celebrity-backed fashion brands struggle due to lack of clear brand identity, inconsistent quality, and market ...

Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...

Permits have been filed for the construction of a 4-story residential building at 1848 Guerlain St. in the Parkchester neighborhood of the Bronx.

The company is developing injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. Its most advanced candidate, MET-097i is a ...

Scott and Federico are safe." In other moves, Nush is now the clear 5/1 second favourite behind Ray. Her odds to win have been cut from 6/1 to 5/1.

Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its common stock to the public at $18.00 per share, the company's shares opened ...

A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...

(“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related ...

Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...